# Viyash Scientific: Analyzing Future Growth and Business Scalability in the Pharmaceutical Sector

> This investment thesis provides a deep dive into Viyash Scientific, evaluating its competitive positioning within the pharmaceutical industry. The analysis explores critical performance drivers including management efficiency, business model durability, and future growth trajectories under various market scenarios. Investors will gain insights into the risk-reward profile of stock 512529 through a comprehensive evaluation of its operational strategy and long-term potential.

**Companies**: Viyash Scientific
**Sectors**: Pharmaceuticals
**Published**: 2026-04-15
**Last Updated**: 2026-04-15
**Source**: https://thesisloop.ai/thesis/60e7acec-1875-4391-94c0-11724c6c6d6b

## Score Overview

| Company | Management | Business Model | Future Growth | Risk |
|---------|-----------|---------------|--------------|------|
| Viyash Scientific | 77/100 | 70/100 | 69/100 | 63/100 |

## Viyash Scientific (BSE:512529)

**Sector**: Pharmaceuticals | **Industry**: Pharmaceuticals

### Management Credibility

- **[CATALYST] Biosecure Act and China-Plus-One** (NEUTRAL): The company is focusing on CDMO opportunities, expecting to generate INR 70-90 crores from this segment in the current year. — target: INR 70-90 crores (+2 more commitments)
  > this year we will end up doing 70 crores to 90 crores on CDMO. It's either CDMO or CMO for big players. This year it's going to go INR 70 crores-INR 90 crores.
- **[CATALYST] Blockbuster Drug Patent Cliff** (NEUTRAL): Targeting the 2025-2030 patent cliff opportunity estimated at $250bn-300bn. — target: $250bn-300bn opportunity
  > 2025-2030 patent cliff: Large number of APIs coming off patent... estimated opportunity of ~$250bn-300bn
- **[METRIC] ANDA Filing and Approval Pipeline** (POSITIVE, MET): The company has already executed 8 launches in the current year, meeting the annual target within the first half of the fiscal year. (2 met, 1 in progress across 3 tracked commitments)
  > And currently, we have around 20-plus products on the pipeline and we are actually expected 10 to 15 products development as well as filing this year as anticipated.
- **[METRIC] Field Force Productivity per MR** (POSITIVE, MET): Management confirmed that the field force expansion to 200 personnel in the previous year is now yielding results in the Indian Animal Health segment. (1 met across 1 tracked commitment)
  > We expect the impact of our field force expansion to kick in during the second half of the year. As we have said earlier, India remains a key market for us to develop.
- **[METRIC] R&D Spend as Percentage of Revenue** (POSITIVE, EXCEEDED): The R&D pipeline has expanded to 17 products as of Q3 FY26. (1 exceeded across 1 tracked commitment)
  > We started actually relooking at our R&D expansion. This year, you can see definitely our R&D expansion, both space as well as people. So next year, we will come up with strong CDMO.
- **[PRINCIPLE] API Backward Integration Advantage** (NEGATIVE, MISSED): SeQuent's standalone API sales for Q2 FY26 were INR 83 crore (830 Mn), failing to meet the INR 100 crore quarterly run rate target. (1 missed across 1 tracked commitment)
  > And also most important factor to sustain US business today is a fully vertical or backward integrated for all our key products. We are done for almost all our key products 45% of our volume products we are done.
- **[TREND] Shift to Complex and Specialty Generics** (NEUTRAL): Transitioning the US portfolio towards complex generics. (+3 more commitments)
  > Our target would be that we should double the contribution of companion animals in the next 3 years in our portfolio.
- **[TREND] Formulation Export Diversification** (NEUTRAL): The company is initiating a new distribution agreement with Boehringer Ingelheim to distribute companion animal products in India starting February. — target: N/A (+2 more commitments)
  > And as you know, we have already signed an exclusive distribution agreement with the Boehringer Ingelheim... We are going to start distributing sometime in February and this is a one opportunity for expand to entire companion animal business in India.
- The company has significantly surpassed the 'high teens' target, achieving a 21% EBITDA margin in the first reported quarter of the merged entity. (2 exceeded, 3 met across 5 tracked commitments) (POSITIVE, EXCEEDED)
  > You would recall that a few quarters ago, we had set ourselves a target of crossing 15% EBITDA and moving to high teens. We are now firmly on that path while also improving our profit after tax substantially.

### Business Model

- **[CATALYST] Biosecure Act and China-Plus-One** (POSITIVE, Change: EXPANDING): The company is shifting focus toward CDMO (Contract Development and Manufacturing) for complex generics and innovators, leveraging its R&D capabilities. (1 shifted, 1 expanding)
  > Yes, absolutely. This year, that's one of the key focus, actually expanding CDMO business as well as complex products development.
- **[CATALYST] US FDA Inspection Normalization** (POSITIVE, Change: EXPANDING): The regulatory moat has expanded significantly. The combined entity now boasts 15 manufacturing plants, 10 of which are USFDA approved, up from the previous count of 10 total facilities. (3 expanding)
  > Combined API Manufacturing Network : 10 facilities with global approvals... US FDA, EU GMP, WHO GMP, KFDA, ANVISA, PMDA
- **[METRIC] API Import Dependence Ratio** (POSITIVE, Change: CONTRACTING): The API segment showed modest full-year growth of 4%, reaching ₹3,378 million. However, the latest quarter (Q4 FY25) saw a 9% decline compared to the same period last year, indicating a short-term slowdown in this segment. (1 contracting, 1 expanding)
  > APIs 869 (Q4 FY25) ... 959 (Q4 FY24) ... (9%) YoY Gr%
- **[METRIC] Field Force Productivity per MR** (POSITIVE, Change: EXPANDING): The India business is expanding through field force additions and new product introductions, with a second phase of expansion planned for FY26. (3 expanding, 1 stable)
  > The formulations business in India... has resulted in a 13% year-on-year sales growth, which we expect to accelerate in the coming year.
- **[METRIC] R&D Spend as Percentage of Revenue** (POSITIVE, Change: EXPANDING): The R&D moat is expanding with the addition of Viyash's capabilities, bringing the total R&D resource count to over 200 and focusing on complex generics and oncology. (3 expanding, 1 shifted)
  > Roughly we have 200 plus scientists including 20 plus doctorates and we have dedicated support team for CDMO... having specialized capabilities such as cytotoxic handling and process safety infrastructure.
- **[PRINCIPLE] API Backward Integration Advantage** (POSITIVE, Change: EXPANDING): The moat is being strengthened through the proposed merger with Viyash Life Sciences, which brings high backward integration and cost leadership in large volume products. (5 expanding)
  > most important factor to sustain US business today is a fully vertical or backward integrated for all our key products. We are done for almost all our key products 45% of our volume products we are done.
- **[PRINCIPLE] US FDA Compliance Binary Risk** (POSITIVE, Change: EXPANDING): The regulatory moat is being reinforced with the combined entity now having 16 manufacturing facilities (7 from SeQuent and 9 from Viyash) with major global approvals. (1 expanding)
  > SeQuent has seven manufacturing facilities... Viyash has 9 USFDA-approved plants
- **[PRINCIPLE] US Generics Pricing Structural Decline** (NEGATIVE, Change: CONTRACTING): The US market continues to face headwinds, showing a slight contraction of 1% YoY and a sharp 26% decline compared to the previous quarter as the company transitions to complex generics. (1 contracting)
  > USA 988 [Q3 FY26] ... YoY Gr% -1%
- **[TREND] API Self-Reliance via PLI Scheme** (POSITIVE, Change: EXPANDING): The API business is showing signs of recovery and margin improvement, with management expecting acceleration starting from Q1 FY26. (4 expanding)
  > The API business reported a revenue of INR3,378 million, reflecting a growth of 4% on a year-on-year basis.
- **[TREND] Shift to Complex and Specialty Generics** (POSITIVE, Change: SHIFTED): The USA segment is now specifically identified as 'USA (Human Health)' following the Viyash merger update, contributing 23% of combined Formulations revenue. It is a key pillar of the 'Sequent 3.0' strategy. (3 shifted, 1 new, 1 expanding)
  > USA (Human Health) 23% of FY25 Formulations Revenue
- **[TREND] Formulation Export Diversification** (POSITIVE, Change: EXPANDING): The Formulations segment continues to be the primary growth engine, with revenue increasing to ₹11,858 million for FY25, representing a 19% YoY growth. Its share of total global sales remains dominant at approximately 77%. (5 expanding)
  > Europe 1,790 [Q3 FY26] ... YoY Gr% 34%
- The company has significantly strengthened its distribution moat in India through an exclusive agreement with global giant Boehringer Ingelheim for pet products. (1 expanding across 2 engines) (POSITIVE, Change: EXPANDING)
  > Formulations revenue grew 20% to 4.8 billion. While API revenue rose 2.9% to 3.6 billion.

### Future Growth

- **[CATALYST] Biosecure Act and China-Plus-One** (POSITIVE, Trend: NEW_TREND): The CDMO segment is a new and accelerating trend for the company, with 3 new contracts signed recently and a focus on complex generics and innovator life cycle management. (1 accelerating, 4 new trend across 5 signals, 1 leading indicator)
  > CDMO market size in India ($Bn) 2024: 23, 2029: 45 (2x)
- **[CATALYST] Blockbuster Drug Patent Cliff** (POSITIVE, Trend: NEW_TREND): The company is actively positioning its R&D pipeline to capture the patent cliff, with 25+ products currently in the Viyash R&D pipeline and 10+ First-to-File (FTF) products in the new portfolio. (4 new trend across 4 signals)
  > 2025-2030 patent cliff: Large number of APIs coming off patent... estimated opportunity of ~$250bn-300bn
- **[CATALYST] US FDA Inspection Normalization** (POSITIVE, Trend: STEADY): The company successfully cleared 5 regulatory inspections in a single quarter, including US FDA and EU audits, demonstrating high manufacturing standards. (2 steady across 2 signals)
  > So we had five regulatory inspections last quarter. In fact, one day, we had two US FDA audits in two sites and one Europe audit in the same month... all went through very well.
- **[METRIC] ANDA Filing and Approval Pipeline** (NEUTRAL): The company is actively filing for new drug approvals globally, with 9 new filings across various international health authorities this quarter.
  > 9 Filings – SFDA(3), EDQM (1) TGA (1), EDMF (2), WHO (1), TW (1)
- **[METRIC] API Import Dependence Ratio** (POSITIVE, Trend: STEADY): The company is steadily optimizing its large manufacturing base, focusing on opex reduction through higher capacity utilization (currently 60-65%). (2 steady across 2 signals)
  > our current capacity utilization is around 60%, 65%. When the revenue is growing, our opex percentage is continuously coming down.
- **[METRIC] R&D Spend as Percentage of Revenue** (NEUTRAL): The company has a robust pipeline of 17 new products in development to fuel future growth.
  > R&D Pipeline 17 Products
- **[PRINCIPLE] API Backward Integration Advantage** (POSITIVE, Trend: ACCELERATING): Viyash continues to improve its gross margins through vertical integration, with Q1 FY26 gross profit margins reaching 58.0%, up from 53.5% in the prior year. (2 accelerating, 2 new trend, 1 steady across 5 signals, 1 leading indicator)
  > And also most important factor to sustain US business today is a fully vertical or backward integrated for all our key products. We are done for almost all our key products 45% of our volume products we are done.
- **[TREND] Formulation Export Diversification** (POSITIVE, Trend: ACCELERATING): Formulations growth is accelerating, particularly in Emerging Markets which saw a 42% YoY jump in Q4 FY25, while the overall segment grew 19% for the full year. (5 accelerating across 5 signals, 2 leading indicators)
  > Formulations 4,809 4,009 20%
- The combined entity (SeQuent + Viyash) is showing accelerating revenue growth, with the full year FY25 reaching ₹30,094 Million, a 12.3% increase over the previous year. (5 accelerating across 5 signals, 1 leading indicator) (POSITIVE, Trend: ACCELERATING)
  > Revenue from operations for Q3 FY'26 was INR 858 crores grown up by 11% year-on-year.

### Risk Assessment

- **[METRIC] ANDA Filing and Approval Pipeline** (NEUTRAL, Risk: MODERATE): The risk is stable; while timelines remain long (12-24 months for some processes), the company received 5 API approvals and 1 finished dose approval this quarter. (2 stable)
  > Some of those things started getting approval next few months but as I explained last call also, it takes 4 months to 18 months.
- **[PRINCIPLE] API Backward Integration Advantage** (POSITIVE): The risk is easing as the company reported a 270-bps improvement in gross margin and a significant rise in EBITDA margins to 15.5%, suggesting one-time costs are being absorbed by operational gains. (2 easing)
  > there was a 270-bps improvement in gross margin, and the pre-ESOP EBITDA rose to INR657 million, and that came in at a 15.5% EBITDA.
- **[PRINCIPLE] US FDA Compliance Binary Risk** (NEGATIVE, Risk: HIGH): The company successfully cleared audits by key customers and maintained its 10 USFDA approved plants. Viyash completed 3 regulatory audits and 28 customer audits in Q4 FY25 without reported adverse findings. (5 stable, 1 high-severity)
  > 3 Regulatory Audits 45 Customer audits Facility Inspections
- **[PRINCIPLE] US Generics Pricing Structural Decline** (NEGATIVE, Risk: MODERATE): Viyash saw a 3% sequential revenue decline due to inventory buildup at a customer's end for the US formulation facility, confirming ongoing demand/phasing volatility in this segment. (2 intensifying, 1 easing, 2 stable)
  > initially post COVID there is a lot of stock build up. There is a lot of competition coming from India. That's initially we struggled a little bit on competing the cost from US side.
- **[TREND] Shift to Complex and Specialty Generics** (NEUTRAL): The US Human Health segment (Viyash) contributed 23% of combined formulations revenue in FY25. While overall revenue grew, the company is shifting focus toward complex generics and 'First to File' products to combat commodity pricing. (1 stable)
  > New Portfolio: 10+ CGTs / NCE-1 / First to File (FTF) products. Focus on complex portfolio
- **[TREND] Formulation Export Diversification** (POSITIVE): The risk is easing as management indicates that dependency on the U.S. is limited (35% of business) and they are protected by having local U.S. manufacturing. (1 easing)
  > our dependency on U.S. is not much. So only 35% of the U.S. business, we do formulation. That's, of course, it's a good scenario since we have manufacturing at U.S.
- Exceptional items remain a significant drag on reported profits, totaling INR 1,029 Mn for the combined entity in FY25, primarily driven by merger expenses and contractual bonuses. (2 intensifying, 3 easing, 2 high-severity) (NEGATIVE, Risk: MODERATE)
  > Net debt-to-EBITDA has reduced to less than 4x, a significant strengthening versus the previous year.

### Scenario Analysis

- The primary impact is limited to first-order automation of manual workflows within manufacturing plants to drive margin expansion and counter Chinese import pricing. This efficiency gain leads to a second-order data advantage in acquisition targeting, allowing the company to identify structural synergies more effectively than peers. However, the lack of third-order preparation suggests the company will remain a 'brick-and-mortar' API manufacturer, potentially missing the shift toward AI-accelerated molecule development that could redefine industry speed-to-market. (NEUTRAL)
  > however you can leverage actually data also, to do is there any good acquisition.
- The Iran conflict initially threatens Viyash through Red Sea shipping disruptions, impacting its 41% revenue exposure to Europe and Emerging Markets. However, this triggers a second-order benefit where the company's internal validation of 6 key intermediates and 45% volume backward integration shields its 54% gross margins from petrochemical-linked cost spikes. Ultimately, this resilience facilitates a third-order structural shift, allowing Viyash to capture high-value CDMO contracts from global firms seeking to regionalize supply chains away from volatile trade zones. (POSITIVE)
  > Europe 1,790 [Mn]; Emerging Markets 1,630 [Mn]; Reported Sales 8,584 [Mn]

---
*Generated by [ThesisLoop](https://thesisloop.ai) — AI investment research for Indian equities.*